Insider · CIK 0001380762
Brian Dorsey
Files at SPRY (ARS Pharmaceuticals, Inc.). First filing Dec 13, 2024, latest Dec 13, 2024.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
SPRY: ARS Pharmaceuticals, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 38Weak | ARS Pharmaceuticals, Inc. | $494k 40,000 shares | -190% | - |
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 2, 2025 | SPRY ARS Pharmaceuticals, Inc. | AGrant or award Stock option (right to buy)derivative | +261,900 | $0.00 | $0 | 261,900 | Jan 3, 2025 |
| Dec 11, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +15,000 | $0.64 | $9,600 | 21,024 | Dec 13, 2024 |
| Dec 11, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -15,000 | $12.43 | $186k | 6,024 | Dec 13, 2024 |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Common Stock10b5-1 | +25,000 | $0.64 | $16k | 31,024 | Dec 13, 2024 |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | SOpen-market sale Common Stock10b5-1 | -25,000 | $12.30 | $307k | 6,024 | Dec 13, 2024 |
| Dec 11, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -15,000 | $0.00 | $0 | 46,828 | Dec 13, 2024 |
| Dec 12, 2024 | SPRY ARS Pharmaceuticals, Inc. | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -25,000 | $0.00 | $0 | 21,828 | Dec 13, 2024 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.